ReviewMolecular biology reports2026
Silencing with precision: In silico strategies for antisense oligonucleotide engineering.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutics based on nucleic acids are emerging as a transformative drug class in the era of personalized medicine. They include antisense oligonucleotides (ASOs), aptamers, small interfering RNAs (siRNAs), small activating RNAs (saRNAs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), in addition to messenger RNAs (mRNAs). ASOs are short synthetic molecules of nucleic acids designed to bind to specific RNA molecules to allow for precise modulation of gene expression in a personalized medicine context. This review will summarize the state of the art in in silico tools and methods that are used for the design, 3D structural prediction, molecular docking, and simulation of ASOs, including their applications and limitations. By leveraging these computational approaches, the review will provide in silico methodologies toward improved specificity and efficacy of ASO therapeutics. These methodologies can enhance understanding of biological mechanisms of ASOs to allow for improved accuracy and efficacy of ASOs in the clinic while also providing new pathways toward the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.